Psychedelic Science Review Editor Barb Bauer conducts a review of some landmark studies.
Three doses of fluoxetine were needed to elicit the effects of one dose of noribogaine.
This is the first preclinical study to examine the anti-depressive effects of ibogaine and noribogaine.
Results support the idea that serotonin 5-HT2A receptor-directed therapeutic strategies may be superior to ketamine-based treatments for depression.
Recent research suggests that psilocybin causes changes in amygdala activity opposite to those seen in conventional antidepressant treatment.
After 4.5 years, 60-80% of the study participants with life-threatening cancer still experienced significantly decreased anxiety or antidepressant effects.
Some changes occured to biomarkers for stress and inflammation. The subjective effects reveal more evidence of the entourage effect.
Usona Follows COMPASS in Receiving Breakthrough Therapy Designation for Psilocybin to Treat Depression
This means the FDA will work to expedite the development and review of psilocybin so it can get to patients with major depressive disorder as soon as possible.
Usona Institute Beginning Phase 2 Clinical Trials Using Psilocybin to Treat Major Depressive Disorder
Enrollment of study volunteers is expected to start within the next two months.
Increased mindfulness and decreased anxiety, depression, and stress were seen right away, becoming more significant four weeks after dosing.